A collaborative breast cancer research project has received funding through the Fiscal Year 2025 Breast Cancer Research Program Breakthrough Award, administered by the Congressionally Directed Medical Research Programs (CDMRP). The award recognises the scientific merit, innovation, and collaborative strength of the research teams led by Dr Katerina… Read More
Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology. The trial (NCT06358573) analyses… Read More
Pharmaceutical company Astex has entered an exclusive worldwide research agreement with Genentech to identify treatments for breast cancer. The partnership will aim to find small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer, leveraging Astex’s fragment-based drug discovery programme. Under the terms of… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW. This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer. The… Read More
Researchers have identified which breast cancer patients should be treated with anthracyclines and who can safely avoid side effects of the drugs, a study shows. Scientists from precision oncology company Agendia published a paper in JCO Precision Oncology, which demonstrates HER2-negative (HR+HER2-) early-stage breast cancer (EBC) patients are most… Read More
Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London (UCL) has found. The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) followed more than 4,400 patients… Read More
First-in-human data from a study into a radioligand therapy (RLT) targeting metastatic breast cancer is set to be announced. Radiopharmaceutical company Affibody will present the data on ABY-271, the HER2-targeting RLT candidate, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. The event will… Read More
News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW. This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health. The… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More
News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW. This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis. The top stories: … Read More
New research has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC). The study, published in Genome Medicine and funded by the charity Breast Cancer Now and others, pinpoints important genes that could be targeted by new drugs. Read More
The US Food and Drug Administration (FDA) has granted Fast Tack Designation for an immune medicine targeting triple-negative breast cancer. RPTR-1-201 is a novel T cell receptor (TCR) bispecific immune medicine, developed by biotechnology company Repertoire Immune Medicines, that is currently in a Phase I/II trial for the… Read More
DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and… Read More
Biotechnology company Anixa Biosciences has partnered with Cytovance Biologics to support the Phase II clinical trial of a breast cancer vaccine. The vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a lactation-associated protein that is typically expressed only in breast tissue during lactation but which re-emerges in many forms of breast cancer. … Read More
A new discovery into how breast cancer spreads could pave the way for a new treatment. Researchers at the University of California San Diego found an inflammatory protein, TYK2, is involved in the process by which cells sense and respond to their physical environment, known as mechanotransduction. … Read More
